Phi Pharma SA New
  • Home
  • About us
    • company
    • management
    • scientific advisors
    • board of directors
    • Contact
  • Technology
  • Programs
  • Partnerships
  • News

Programs

Phi Pharma's initial focus in on innovative peptide drug conjugates against multiple myeloma, acute myeloid leukaemia and other B-Cell derived malignancies. In parallel, peptide drug conjugates against solid tumours such as ovarian and colorectal cancer have been investigated. Programmes are in in-vivo Proof of Concept and lead-selection/optimisation phase. An adoptive transfer mouse model of a leukaemia cell line has provided proof of concept for the AML programme.
Phi Pharma SA - Lausanne and Sion, Switzerland
info@phi-pharma.com

© 2021 Phi Pharma SA